The central challenge the researchers set out to address is a familiar one in human genetics. GWAS have catalogued hundreds of genetic loci associated with neuropsychiatric disorders, but these signals typically point to broad genomic regions rather than to specific causal genes, and they say little about which tissues or cell types mediate the association. The specific genes and proteins underlying susceptibility, and their tissue- and cell type-specific manifestations, remain poorly understood, which has hindered the development of targeted therapies. Mendelian randomisation offers a way around this impasse by exploiting naturally occurring genetic variation as a form of randomised trial: if genetic variants that influence protein levels also influence disease risk, that pattern supports a causal role for the corresponding protein rather than a mere correlation.

Technically, the approach works by combining three layers of summary statistics. First, GWAS data identify genetic variants associated with each disorder. Second, quantitative trait locus (QTL) studies, which map genetic variants that influence gene expression or protein abundance, provide the intermediate molecular phenotypes. The team drew on both blood and brain QTL resources, recognising that neuropsychiatric disorders involve biology in both compartments. Third, a Bayesian colocalisation and prioritisation framework evaluates whether the same causal variant drives both the molecular phenotype and the disease, assigning each gene-protein association a posterior probability. Only associations with a posterior probability of at least 0.7 were considered significant, a threshold designed to filter out signals that could be explained by linkage disequilibrium, the tendency of nearby variants to be inherited together.

What distinguishes this study from earlier efforts is its resolution down to individual brain cell types. By incorporating single-cell expression data, the researchers were able to resolve eleven of their significant brain associations to specific cell populations. This matters because the brain is extraordinarily heterogeneous: a signal that appears in bulk tissue may actually originate from a small population of cells, and knowing which cells carry the molecular signature can transform how a target is interpreted and pursued therapeutically. Among the newly resolved signals were TRAF3, associated with Alzheimer’s disease and multiple sclerosis in excitatory neurons, and SCFD1, associated with amyotrophic lateral sclerosis in both excitatory and inhibitory neurons, extending earlier findings for established disorder-related genes by pinpointing where in the brain they act.

The most striking results were three previously unreported brain-specific gene-protein signatures. The first, TRMT61B, was associated with both major depressive disorder and Parkinson’s disease in bulk brain tissue. TRMT61B encodes a methyltransferase component of the mitoribosome, the ribosome responsible for synthesising proteins inside mitochondria, the energy-producing organelles of the cell. Its association implicates mitoribosome remodelling and mitochondrial translation in susceptibility to both disorders, a finding that resonates with long-standing but poorly understood links between mitochondrial dysfunction and conditions affecting mood and movement.

The second novel signature, EEFSEC, was associated with schizophrenia in bulk brain and specifically in excitatory neurons. EEFSEC is a specialised translation elongation factor required for the incorporation of selenocysteine, a rare amino acid, into selenoproteins, several of which are critical for antioxidant defence and redox balance in the brain. The authors interpret this association as pointing toward serotonergic signalling dysregulation in the pathophysiology of schizophrenia, adding a molecular dimension to hypotheses about neurotransmitter system disruption in the disorder. The third signature, SLC25A24, was associated with schizophrenia in bulk brain and, at single-cell resolution, across astrocytes, excitatory neurons, oligodendrocytes and oligodendrocyte progenitor cells. SLC25A24 is a mitochondrial solute carrier involved in calcium-sensitive signalling, and its association suggests a role for disrupted mitochondrial homeostasis in schizophrenia that cuts across multiple cell types rather than being confined to neurons alone.

Beyond identifying causal genes, the researchers pursued the translational implications of their findings through two complementary analyses. Pathway enrichment analyses were used to delineate the functional pathways underlying the candidate gene-protein signatures, grouping the implicated genes into biological processes that may be amenable to pharmacological modulation. Separately, the team queried the Connectivity Map, a widely used database that links gene expression signatures to small-molecule compounds, to prioritise therapeutic compounds that map to NPD-specific gene-protein signatures. They also used ExPheWAS, an approach that systematically screens genetic associations against a broad spectrum of phenotypes, to flag potential off-target side effects before any candidate advances toward the clinic.

One result stands out from this drug-repurposing arm of the study: bortezomib, a proteasome inhibitor already approved for the treatment of multiple myeloma, emerged as a potential candidate for repurposing in schizophrenia. The logic of the approach is that if the gene-expression signature produced by a compound counteracts the disease-associated signature identified through the genetic analysis, the compound may have therapeutic value even if it was developed for an entirely different indication. Repurposing approved drugs has the practical advantage that safety profiles are already established, potentially shortening the path to clinical evaluation. The ExPheWAS screening for off-target effects is a deliberate safeguard in this process, designed to anticipate unwanted phenotypic consequences of modulating the identified targets.

The study’s scope deserves emphasis. By analysing eleven common neuropsychiatric disorders within a single unified framework, the authors could compare molecular mechanisms across diagnostic boundaries, identifying both shared and disorder-specific signatures. This cross-disorder perspective is increasingly recognised as essential in neuropsychiatry, where genetic risk variants often show pleiotropic effects, influencing more than one condition. The finding that TRMT61B is associated with both major depressive disorder and Parkinson’s disease is a case in point, suggesting that mitochondrial translation may represent a convergent biological pathway relevant to disorders that are usually treated as distinct clinical entities.

The work, led by researchers at the Mater Research Institute at The University of Queensland, the Menzies Institute for Medical Research at the University of Tasmania, and West China Hospital of Sichuan University, was supported by the Mater Foundation, the Australian National Health and Medical Research Council, Multiple Sclerosis Australia, and internal funds from West China Hospital. The authors acknowledge that their findings, like all Mendelian randomisation results, generate hypotheses that will require experimental validation in cellular and animal models before therapeutic implications can be realised. Nevertheless, by resolving gene-protein associations at tissue and cell-type resolution, the study provides a framework for advancing mechanistic understanding of neuropsychiatric risk and, crucially, for identifying druggable targets and repurposing opportunities that could accelerate the development of desperately needed treatments for disorders that have proven stubbornly resistant to conventional drug discovery efforts.

Subject of Research: Identification of causal genes and therapeutic targets for neuropsychiatric disorders using joint analysis of GWAS and blood and brain QTL summary statistics

Article Title: Joint analysis of GWAS and blood and brain QTL summary statistics reveals potential therapeutic targets for neuropsychiatric disorders

Article References: Yang, Y., Zhou, Y., Lin, X., Wu, Y., & Gratten, J. (2026). Joint analysis of GWAS and blood and brain QTL summary statistics reveals potential therapeutic targets for neuropsychiatric disorders. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08603-y

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08603-y

Keywords: neuropsychiatric disorders, Mendelian randomisation, GWAS, QTL, multi-omics, schizophrenia, major depressive disorder, Parkinson's disease, drug repurposing, bortezomib, mitochondrial translation, single-cell genomics

The research, led by Jin Yan, Qianhai Fang, Hailiang Zhang, and Yachun Wang of China Agricultural University, together with Bin Li of the Academy of Agriculture and Animal Husbandry of Xizang Autonomous Region in Lhasa, compared peripheral blood mononuclear cells, or PBMCs, from Holstein cows living at high and low altitudes. PBMCs are a window into the circulating immune system, and because they are readily accessible and highly responsive to physiological stress, they are an ideal tissue for interrogating how an animal adapts to chronic environmental pressure. The team used RNA sequencing to capture the full transcriptional landscape of these cells, cataloguing both messenger RNAs and long non-coding RNAs, the latter being a class of regulatory molecules that do not encode proteins but can influence gene expression through a variety of mechanisms.

The scale of the differential expression they uncovered is striking. In total, the analysis identified 7,625 differentially expressed genes and 4,956 differentially expressed long non-coding RNAs between the high-altitude and low-altitude groups. That such a large fraction of the transcriptome shifts with altitude suggests that chronic hypoxia is not a subtle perturbation for these animals; it is a systemic challenge that reorganizes cellular priorities. The cows sampled in Tibet face a sustained reduction in partial oxygen pressure, and their blood cells appear to be running a fundamentally different transcriptional program compared with their counterparts near sea level in Beijing.

When the researchers subjected those differentially expressed genes to functional enrichment analysis, a coherent biological story emerged. Among the downregulated genes, two interconnected pathways stood out: mitochondrial translation and oxidative phosphorylation. Both processes are central to how cells generate energy from oxygen. Oxidative phosphorylation is the chain of protein complexes in the inner mitochondrial membrane that couples electron transport to ATP synthesis, and mitochondrial translation supplies the essential protein components of that machinery, encoded by the mitochondrial genome itself. Downregulation of these pathways at high altitude suggests a recalibration, or perhaps a constrained capacity, of the very system that consumes oxygen most heavily. In hypoxic conditions, cells often shift away from oxidative metabolism toward glycolysis, a phenomenon long recognized in mammalian hypoxia biology, and this transcriptomic signature is consistent with such a metabolic reprogramming in the blood cells of oxygen-starved cows.

At the same time, genes involved in immune-related processes were enriched among the upregulated set. This is not merely incidental. Hypoxia is a well-known modulator of immune function, and the hypoxia-inducible factor, or HIF, pathway sits at the crossroads of oxygen sensing and inflammatory signaling. Chronic low oxygen can activate immune cells, alter cytokine production, and shift the balance of immune responses. The finding that high-altitude Holsteins show enhanced expression of immune-related processes in their circulating mononuclear cells suggests that their immune systems are in a state of heightened engagement, potentially reflecting both the physiological strain of hypoxia and any associated health challenges that come with it. For high-yielding dairy cows, whose immune competence is already under pressure from lactation demands, this added immune activation could have practical consequences for disease resistance and productivity on the Tibetan plateau.

What elevates the study beyond a conventional differential expression analysis is its integrated treatment of long non-coding RNAs. These molecules have moved from the margins of genomics to its center over the past two decades, yet in livestock species they remain poorly charted. The researchers did not simply count the differentially expressed lncRNAs; they built a multi-layered framework to infer which of them might actually regulate which protein-coding genes. The approach combined three independent lines of evidence. First, cis-acting positional analysis identified lncRNAs located near, and potentially acting upon, neighboring genes, exploiting the well-established principle that many lncRNAs regulate genes on the same chromosome through local chromatin effects. Second, weighted gene co-expression network analysis, or WGCNA, grouped transcripts into modules whose expression patterns correlate across samples, revealing which lncRNAs travel with which genes under altitude-related conditions. Third, RNAplex, a tool that predicts thermodynamically stable RNA-RNA interactions, was used to filter candidate pairings for plausible direct binding, assessing minimum free energy of hybridization to separate signal from noise.

The convergence of these methods produced a set of candidate lncRNA-mRNA associations that the authors describe as co-expression relationships supported by multiple criteria. Among the core lncRNAs that emerged, one stands out: MSTRG.54387.36, identified as a cis-acting partner of CD274. That gene name will be familiar to immunologists, because CD274 encodes PD-L1, the ligand that engages the PD-1 immune checkpoint pathway, a central regulator of immune suppression that has become famous in cancer immunotherapy. A non-coding RNA physically positioned near PD-L1 and co-expressed with it in hypoxia-stressed immune cells is a compelling observation, given that PD-L1 expression is known to respond to hypoxic signaling. It raises the possibility that in high-altitude Holsteins, a non-coding RNA participates in tuning the checkpoint pathways that govern immune cell activity, linking oxygen availability to immune regulation through a mechanism that has been little explored in cattle.

The authors are careful to frame these findings as candidate associations rather than proven regulatory interactions. Co-expression, genomic proximity, and predicted RNA-RNA binding are indicative, not definitive, and the study is explicitly presented as groundwork for future experimental dissection of altitude adaptation mechanisms. That caution is appropriate, and it does not diminish the value of the resource the study creates. The supplementary data accompanying the paper include detailed tables of differentially expressed mRNAs, characteristics of known and novel lncRNAs, cis-acting target predictions, co-expression networks, and RNAplex-supported trans-acting pairs, providing a rich, publicly accessible map for researchers who want to test specific interactions in the laboratory.

The practical implications extend beyond basic biology. Holstein cattle are being raised at increasingly diverse elevations as dairy production expands into regions such as the Tibetan plateau, where hypoxia limits both animal welfare and productivity. Identifying the transcriptomic signatures of chronic hypoxia response, and pinpointing candidate regulatory RNAs within them, offers breeders and geneticists potential molecular markers for altitude tolerance. If future work confirms that specific lncRNAs modulate the immune and metabolic responses of high-altitude cows, those loci could be incorporated into genomic selection programs, allowing breeding decisions that account for environmental adaptation as well as milk yield. In a warming, crowded world where agriculture is pushed into ever more marginal environments, understanding the genetic architecture of stress adaptation in livestock becomes an economic and ethical necessity, not a curiosity.

There is also a broader scientific resonance. The study adds to a growing body of evidence that the non-coding transcriptome is an integral part of how mammals cope with hypoxia, from high-altitude human populations in Tibet and the Andes to yaks and other hypoxia-tolerant species. By documenting the coordinated shift of oxidative phosphorylation, mitochondrial translation, and immune pathways in a commercially vital breed, and by nominating specific regulatory RNAs for follow-up, the work connects livestock genomics to fundamental questions in hypoxia biology. The image of a Holstein cow grazing on the Tibetan plateau, her blood cells quietly reorchestrating thousands of transcripts and non-coding regulators to keep her alive and lactating in thin air, is a vivid reminder that adaptation is written not only in the protein-coding genome but in the vast, still-mysterious RNA world that surrounds it.

Subject of Research: Transcriptomic response of Holstein cattle to chronic high-altitude hypoxia, including mRNA and lncRNA expression in peripheral blood

Article Title: Integrated analysis of mRNA and lncRNA transcriptomes in peripheral blood of Holstein cattle at high and low altitudes

Article References: Yan, J., Fang, Q., Li, B., Zhang, H., & Wang, Y. (2026). Integrated analysis of mRNA and lncRNA transcriptomes in peripheral blood of Holstein cattle at high and low altitudes. BMC Genomics. https://doi.org/10.1186/s12864-026-13383-6

Image Credits: AI Generated

DOI: 10.1186/s12864-026-13383-6

Keywords: Holstein cattle, hypoxia adaptation, lncRNA, transcriptomics, RNA sequencing, peripheral blood mononuclear cells, oxidative phosphorylation, mitochondrial translation, immune regulation, CD274, WGCNA, altitude adaptation

The logic of the field has shifted because metabolites themselves turn out to be messengers. S-adenosylmethionine, or SAM, a product of one-carbon metabolism, serves as the methyl donor for chemical marks placed on mitochondrial DNA, including 5-methylcytosine and the bacteria-like N6-methyladenine. The methyltransferase METTL4 installs 6-methyladenine on mitochondrial DNA, which disrupts binding of the transcription factor TFAM and suppresses mitochondrial transcription. Hypoxia strongly induces METTL4 in liver and breast cancer cells, throttling mitochondrial metabolism precisely when tumors want it restrained. Methylation of the mitochondrial genome appears to protect it from oxidative damage, and DNA methyltransferases DNMT3A and DNMT3B mediate this in embryonic cells — enzymes whose aberrant expression or mutation drives cancer initiation. The picture is complicated, however: the true abundance of 5-methylcytosine on mitochondrial DNA remains debated, with optimized protocols reporting levels of only 0.19 to 0.67 percent in mouse oocytes and human lung carcinoma cells, and technical artifacts such as inefficient bisulfite conversion and mis-mapping of nuclear-integrated mitochondrial sequences continuing to muddy clinical analyses.

The replication machinery itself is equally metabolically entangled. DNA polymerase gamma, POLG, together with its accessory subunit POLG2, copies the mitochondrial genome, and its overactivation has been linked to elevated risk of prostate cancer and acute myeloid leukemia. Proteomic surveys have revealed a dense landscape of post-translational modifications on POLG and POLG2 that couple cellular fuel state to genome maintenance. The acetyltransferase GCN5 acetylates POLG at lysine 1039 using acetyl-CoA as donor, while the NAD+-dependent deacetylase SIRT3 reverses the mark — a push-pull system that reads acetyl-CoA and NAD+ availability directly. In parallel, poly(ADP-ribose) polymerase 1 uses NAD+ to attach ADP-ribose groups to POLG, triggering ubiquitination and degradation. Through these routes, the cell’s energy currency and redox state literally decide how much replication enzyme survives, and cancer cells exploit these metabolite-sensing nodes to rewire mitochondrial function to their advantage.

Transcription is governed by the same logic. The mitochondrial RNA polymerase POLRMT is succinylated at lysine 622, a modification that impairs its DNA-binding activity. The metabolic enzyme SUCLG1, part of the succinyl-CoA ligase complex, restricts mitochondrial succinyl-CoA levels to keep POLRMT hypo-succinylated, sustaining mitochondrial respiration and driving leukemia progression. Succinyl-CoA thus functions as a key metabolic signal bridging mitochondrial metabolism and transcription in both leukemia and solid tumors. TFAM, the packaging factor that recruits POLRMT to promoters, is itself phosphorylated, acetylated, and — most recently — arginine-methylated at position 82 by PRMT5, a modification essential for DNA binding and mitochondrial genome integrity. Loss of PRMT5 leaves breast carcinoma cells vulnerable to mitochondrial DNA damage and oxidative stress, and several PRMT5 inhibitors are already in clinical trials, raising the prospect of attacking tumor bioenergetics through the transcription apparatus itself.

Downstream, RNA processing and ribosome assembly consume enormous metabolic resources. The 12S and 16S ribosomal RNAs of the mitoribosome are studded with SAM-dependent methylation marks: TFB1M dimethylates the 3′ end of 12S rRNA to stabilize the small subunit, NSUN4 methylates cytosine 911, METTL15 installs N4-methylcytidine at position 839, and TRMT61B places N1-methyladenosine at position 947 of 16S rRNA, a modification conserved across all vertebrates that stabilizes local ribosome structure. Strikingly, when SAM is depleted, unprocessed pre-rRNA accumulates and mitoribosome assembly grinds to a halt. The same SAM pool feeds transfer RNA modifications, including the taurine-and-GTP-dependent wobble modification 5-taurinomethyluridine installed by GTPBP3 and MTO1, which is essential for translation fidelity — and, notably, MTO1 upregulation in melanoma sustains oxidative phosphorylation and confers resistance to vemurafenib. The dioxygenase ALKBH7, which depends on alpha-ketoglutarate and oxygen to erase methylation marks that otherwise delay transfer RNA maturation, adds another metabolite-gated checkpoint to the pipeline.

At the level of protein synthesis, the review highlights an increasingly granular view of mitoribosome regulation. Human mitoribosomes contain three iron-sulfur clusters installed by GLRX5 and BOLA3, enzymes with prognostic value in bladder cancer and lung adenocarcinoma, while METTL17 carries a [4Fe-4S] cluster that confers redox-sensing activity to protein synthesis. Lipid metabolism matters too: cardiolipin, enriched in cristae membranes where mitochondrial protein synthesis is spatially confined, promotes the inner-membrane docking of ribosomes, and the remodeling enzyme tafazzin maintains the membrane curvature this requires. Perhaps the most striking recent discovery is lactylation — the attachment of lactate-derived lactyl groups to proteins — now documented on TFAM and multiple ribosomal proteins in clinical tumor tissues, and linked to chemoresistance and metastasis in breast, kidney and lung cancers. Lactate, once dismissed as waste, is actively consumed by mitochondria as fuel and now appears to write epigenetic marks on the very machinery that builds the respiratory chain.

The mitochondrial genome also hides a second layer of coding information. Beyond its thirteen canonical proteins, it produces microproteins with potent biological activity. Humanin, a 24-amino-acid peptide, suppresses apoptosis by interfering with Bax activation; it is elevated in the serum of breast cancer patients and accelerates tumor growth, lung metastasis, glioblastoma invasion and temozolomide resistance in experimental models. MOTS-c, a 16-amino-acid peptide from the 12S rRNA open reading frame, activates AMPK and shows context-dependent effects — circulating levels rise in prostatic precancerous lesions and hepatocellular carcinoma yet fall in adrenal tumors, while in liver cancer MOTS-c promotes apoptosis under hypoxia and suppresses tumor growth. Additional peptides such as the SHLP family, SHMOOSE and CYTB-187AA underscore that the mitochondrial central dogma generates unanticipated regulators whose roles in cancer are only beginning to be mapped.

The translational payoff is substantial. The allosteric POLRMT inhibitor IMT1B blocks mitochondrial transcription with minimal toxicity in normal tissues and suppresses leukemia, endometrial carcinoma and other tumors in preclinical models. The thymidine analog alovudine inhibits POLG, impairing oxidative phosphorylation in acute myeloid leukemia, while small-molecule activators such as PZL-A allosterically restore mutant polymerase activity. FDA-approved antibiotics quinupristin and dalfopristin inhibit mitochondrial translation and reduce glioblastoma stem cell clonogenicity, and linezolid suppresses T cell metabolism through the same route, with hematological toxicities limiting its use. Inhibition of dihydroorotate dehydrogenase by ML390 starves leukemia cells of pyrimidines needed for mitochondrial biogenesis, and the iron chelator deferoxamine disrupts OXPHOS super-complexes in breast cancer with encouraging selectivity. Genome-wide sequencing has also revealed that colorectal cancer mitochondrial DNA mutations carry prognostic weight, with MT-CYB mutations significantly correlating with poor patient survival.

Perhaps the most futuristic front is mitochondrial genome editing itself. DddA-derived cytosine base editors and TALE-linked deaminases now allow precise CG-to-TA and A-to-G conversions in mitochondrial DNA, and adeno-associated virus vectors have delivered these editors to post-mitotic mouse tissue, while engineered mitoARCUS nucleases have cleared mutant mitochondrial DNA systemically in animal models. Off-target nuclear editing — reported at rates up to 17.5 percent at some sites — and unintended heteroplasmy shifts remain serious concerns, spurring strategies such as nuclear export signals, strand-selective editors like CyDENT, and tumor-specific promoters to restrict editing to cancer cells. The review’s authors close with a call to integrate high-resolution structural biology, single-cell metabolomics and in vivo lineage tracing to decode the spatiotemporal choreography of mitochondrial gene expression. If they are right, the organelle’s second genome — long overshadowed by the nucleus — may prove to be one of the most exploitable weaknesses a tumor carries.

evolutionary backdrop helps explain why this control system is so intricate. Mitochondria descend from a free-living prokaryotic ancestor engulfed more than 1.45 billion years ago, and the long history of metabolic trade-offs with the host cell left the organelle semi-autonomous: most of its roughly 1,500 proteins are nuclear-encoded, yet the thirteen genes retained in the compact circular genome encode core respiratory chain subunits whose expression must be tuned to local energy demand. Because mtDNA copy number varies naturally across tissues, its dysregulation is directly tied to cancer risk, and tumor cells dynamically adjust both genome abundance and gene output to match proliferative and metastatic needs.

Structural organization adds another layer of control. The mitochondrial genome packs into nucleoids within the matrix, with most protein- and rRNA-coding regions flanked by transfer RNA genes, and regulatory marks such as 5-methylcytosine concentrate in the displacement loop, the non-coding region where replication and transcription originate. Recent structural work has also complicated the classic picture of the replicase: POLG2 can contact DNA independently of POLG without altering polymerase activity, hinting at versatile functions beyond processive elongation.

Methodological caveats deserve emphasis for readers weighing the evidence. Detecting low-frequency mitochondrial modifications demands careful technique; antibody-based capture, bisulfite conversion, isotope labelling, HPLC–mass spectrometry and next-generation sequencing each carry distinct biases, and incomplete light-strand coverage can distort tumor measurements. As optimised protocols spread and quantitative data accumulate across tumor types, the field should be better placed to separate genuine metabolic regulation from technical noise, sharpening the therapeutic opportunities this review maps out.

Subject of Research: Metabolic regulation of the mitochondrial central dogma in cancer

Article Title: Exploring mitochondrial central dogma in cancer from a metabolic perspective

Article References: Zhang, S., Han, B., Chen, L., Chen, L., Wang, T., Lin, M., Liu, J., & Wang, Y. (2026). Exploring mitochondrial central dogma in cancer from a metabolic perspective. Clinical Cancer Bulletin, 5(1), Article 19. https://doi.org/10.1007/s44272-026-00071-5

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00071-5

Keywords: mitochondria, mitochondrial DNA, mtDNA replication, POLRMT, TFAM, mitoribosome, RNA modifications, lactylation, mitochondrial translation, humanin, MOTS-c, mitochondrial genome editing